OBJECTIVE To compare platelet function and viscoelastic test results between healthy dogs and dogs with chronic kidney disease (CKD) to assess whether dogs with CKD have platelet dysfunction and altered blood coagulation.
ANIMALS 10 healthy control dogs and 11 dogs with naturally occurring CKD.
PROCEDURES Blood and urine were collected once from each dog for a CBC, serum biochemical analysis, urinalysis, and determination of the urine protein-to-creatinine ratio, prothrombin time, activated partial thromboplastin time, plasma fibrinogen concentration, and antithrombin activity. Closure time was determined by use of a platelet function analyzer and a collagen-ADP platelet agonist. Thromboelastography (TEG) variables (reaction time, clotting time, α angle, maximum amplitude, and global clot strength [G value]) were determined by use of recalcified nonactivated TEG. Platelet expression of glycoprotein Ib (GPIb; receptor for von Willebrand factor), integrin αIIbβ3 (αIIbβ3; receptor for fibrinogen), and P-selectin (marker for platelet activation) was assessed by flow cytometry.
RESULTS Compared with healthy control dogs, the median closure time was prolonged, the median maximum amplitude and G value were increased, and the median clotting time was decreased for dogs with CKD. Platelet expression of both αIIbβ3 and P-selectin was also significantly increased for dogs with CKD, compared with that for control dogs. Platelet expression of GPIb, αIIbβ3, and P-selectin was not correlated with closure time or any TEG variable.
CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that dogs with CKD frequently had evidence of platelet dysfunction and hypercoagulability that were not totally attributable to alterations in platelet surface expression of GPIb, αIIbβ3, and P-selectin.
Objective—To determine the effect of a commercial
bioflavonoid antioxidant on acetaminophen-induced
oxidative injury to feline erythrocytes.
Design—Randomized controlled study.
Animals—45 healthy age-matched cats.
Procedure—Cats were assigned to 3 experimental
groups. Groups 1 and 3 received a bioflavonoid antioxidant
(10 mg/d) orally for 2 weeks. Groups 2 and 3
received an oxidative challenge with acetaminophen
(90 mg/kg [41 mg/lb] of body weight, PO) on day 7.
Packed cell volume, percentage of erythrocytes with
Heinz bodies, blood methemoglobin concentration,
and blood reduced and oxidized glutathione concentrations
were determined at various times during the
2-week study period.
Results—Adverse effects were not associated with
bioflavonoid antioxidant administration alone.
Acetaminophen administration resulted in a significant
increase in methemoglobin concentration in groups 2
and 3; differences were not detected between these
groups. Heinz body concentrations in groups 2 and 3
increased after acetaminophen administration; however,
the increase in cats that received the antioxidant
was significantly less than in group-2 cats. Total blood
glutathione concentrations did not change significantly
in groups 2 and 3 after acetaminophen administration;
however, ratio of reduced to oxidized glutathione
concentration increased significantly after administration
in group-2 cats, compared with group-3 cats.
Conclusions and Clinical Relevance—Oral administration
of bioflavonoid antioxidants to cats at risk for
oxidative stress may have a beneficial effect on their
ability to resist oxidative injury to erythrocytes. (J Am
Vet Med Assoc 2000;217:1157–1161)
Approximately 35% of households in the United States and Canada own 1 or more dogs, totaling an estimated 75 million dogs in the United States and Canada.1,2 Despite continuous development of health promotion and disease prevention products and strategies, infectious disease remains an important contributor to disease and death for dogs. Hundreds of pathogens infectious to dogs have been identified, with more emerging over time.3 Some of these pathogens can also cause disease in people, leading to published recommendations to reduce the risks of human disease associated with animal settings.4,5
Advancing equality and equity in society is creating positive change, and the time has come to critically evaluate veterinary medicine, which, by all metrics, lacks diversity. To keep pace with increasingly diverse demographics and recent surges in pet ownership among all racial/ethnic groups, significant efforts to enhance diversity, equity, inclusion, and belonging (DEIB) must occur in veterinary colleges and the profession. Recruiting more underrepresented students, building pipelines for diverse faculty/staff, and creating inclusive, welcoming environments where all can thrive are critical steps toward enhancing DEIB within our organizations and profession. Our goal is to share experiences and lessons learned from our intentional commitment to strengthen DEIB, with the hope that our journey will be helpful to others. Increasing diversity in the veterinary profession will be facilitated through removing barriers, creating inclusive work environments where all people feel they belong, and ensuring fair and equitable hiring and personnel management practices. These steps should in turn improve access and quality of veterinary care, ensure we are more representative of the communities we serve, increase revenue, and preserve the human-animal bond.
“You cannot change any society unless you take responsibility for it, unless you see yourself belonging to it, and responsible for changing it.”
Viewpoint articles represent the opinions of the authors and do not represent AVMA endorsement of such statements.
“Imperfections are not inadequacies; they are reminders that we’re all in this together.
We don’t have to do all of it alone. We were never meant to.”
In 2016, The Oiho State University (OSU) College of Veterinary Medicine (CVM) began a strategic planning process systematically evaluating 6 crucial domains: 1) institutional culture and sustainability of its people, 2) education and success of our students, 3) innovative and impactful research, 4) features of a highly successful referral veterinary medical center,